FeesSafety
Pluang+

Olin Corp remains a Buy with 20%+ upside, backed by price hikes and strong cash flow despite market challenges.

Market News
03 Nov 2026, 00:21 WIB
Seeking Alpha
View Source
Bullish
Olin Corp remains a Buy with 20%+ upside, backed by price hikes and strong cash flow despite market challenges.

Olin Corporation is rated a Buy with over 20% upside potential due to self-help measures and attractive free cash flow yield. Despite facing weak markets and pressures from Chinese exports, Olin's Q3 results showed margin protection through price increases, improved Winchester volumes, and facility restarts. The company maintains a secure 4.5% dividend supported by strong liquidity and no major debt maturities until 2029. The planned merger with Huntsman is on track for Q1 2027, expected to generate $250–$400 million in synergies, though these may be realized gradually.

Olin Corporation's outlook is noted here with Pluang's Basic Materials sector data for context. For readers following Basic Materials, here is Pluang's market snapshot as of Nov 03, 2026 04:11 WIB: Among 83 priced US stocks, 53 rose and 29 fell. Notable movers include SCCO at USD 178.01 with a 1-day change of -7.17% and Pluang order activity showing 59% Sell / 41% Buy, EXK at USD 7.22 down 6.96% with 38% Sell / 62% Buy activity, and CRH at USD 96.65 up 6.38%. Typical hold times on Pluang range from 9 to 63 days across these stocks.

More News

Zentalis grants 136,000 stock options to new hires under Nasdaq inducement rule

Zentalis grants 136,000 stock options to new hires under Nasdaq inducement rule

Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...

Company Fundamentals
Neutral
53 minutes ago
Dianthus Therapeutics grants stock options to new hires under Nasdaq inducement rule

Dianthus Therapeutics grants stock options to new hires under Nasdaq inducement rule

Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...

Company Fundamentals
Neutral
53 minutes ago
Federal Home Loan Bank of Atlanta elects new directors and appoints 2027 Chair and Vice Chair.

Federal Home Loan Bank of Atlanta elects new directors and appoints 2027 Chair and Vice Chair.

The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...

Neutral
2 hours ago
Solana's real-world asset transfers hit $16.2B in 30 days, up 80%, signaling strong network activity.

Solana's real-world asset transfers hit $16.2B in 30 days, up 80%, signaling strong network activity.

Solana recorded $16.20 billion in real-world asset (RWA) transfers over the 30 days ending Nov. 2, marking an 80.11% increase and indicating heightened token movement on its network. The distributed asset value also rose 17.61% to $5.12 billion, refl...

Protocol Fundamentals
Bullish
5 hours ago
Summit Midstream to report Q3 2026 results on Nov 9, with earnings call on Nov 10.

Summit Midstream to report Q3 2026 results on Nov 9, with earnings call on Nov 10.

Summit Midstream Corporation announced it will release its operating and financial results for the third quarter of 2026 on November 9, after the NYSE closes. The company will hold an earnings call on November 10 to discuss these results. Senior mana...

Company Fundamentals
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App